We characterize a lineage-switching event that occurred during treatment with a menin inhibitor, and find that in the AML patient sample the oncoprotein cofactor ENL remains bound to a subset of oncoprotein-target genes including the GMP-like program, despite the on-target dissociation of the oncoprotein and menin from chromatin. This evidence concerns the gene MEN1 and acute myeloid leukemia.